[{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Transcription factor","graph1":"Oncology","graph2":"Discovery","graph3":"Flare Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Flare Therapeutics \/ Third Rock Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Flare Therapeutics \/ Third Rock Ventures"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"FTX-6746","moa":"PPARG","graph1":"Oncology","graph2":"Preclinical","graph3":"Flare Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Flare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Flare Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"FX-909","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Flare Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Flare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Flare Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"GordonMD Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Series B Financing","leadProduct":"FX-909","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Flare Therapeutics","amount2":0.12,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"","sponsorNew":"Flare Therapeutics \/ GordonMD Global Investments","highestDevelopmentStatusID":"5","companyTruncated":"Flare Therapeutics \/ GordonMD Global Investments"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Caris Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"FX-909","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Flare Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Flare Therapeutics \/ Flare Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Flare Therapeutics \/ Flare Therapeutics"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Flare Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Flare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Flare Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Flare Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : FX-909 is a highly potent and selective inhibitor of PPARG and has demonstrated tumor eradication in preclinical animal models of urothelial cancer at low oral doses.

                          Brand Name : FX-909

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 19, 2023

                          Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : The collaboration focuses to accelerate precision medicine approaches across five of Flare's programs, including its lead precision oncology program, FX-909, a small molecule inhibitor targeting PPARG, into clinical trials through advanced molecular prof...

                          Brand Name : FX-909

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 13, 2023

                          Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Recipient : Caris Life Sciences

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : The net proceeds will be used to support the advancement of FX-909, a first-in-class PPARG inhibitor, into the clinic in 2023, along with continued development of Flare's platform and pipeline of novel transcription factor targets in oncology.

                          Brand Name : FX-909

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 22, 2023

                          Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : GordonMD Global Investments

                          Deal Size : $123.0 million

                          Deal Type : Series B Financing

                          blank

                          04

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : Flare is advancing a novel PPARG inhibitor through Investigational New Drug (IND)-enabling studies and expects to initiate its Phase 1 clinical trial for FX-909 in 2023 in individuals with locally advanced or metastatic UC.

                          Brand Name : FX-909

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 28, 2022

                          Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : FTX-6746, a potent, selective, small molecule PPARG inhibitor (inverse agonist), drives robust PPARG target gene silencing in UC cell lines and drives tumor regression in PPARG-amplified and RXRA-mutant UC xenograft models.

                          Brand Name : FTX-6746

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 26, 2022

                          Lead Product(s) : FTX-6746

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : The Series A will support Flare’s further advancement of its lead program in precision oncology toward the clinic. In addition, the company will continue to build its unique engine and proprietary assays to discover small molecules.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 13, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Third Rock Ventures

                          Deal Size : $82.0 million

                          Deal Type : Series A Financing

                          blank